Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Real-time Estimate Cboe BZX  -  09:46 2022-11-28 am EST
35.88 USD   +0.43%
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08/17/2022 | 04:02pm EST

NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates. The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to the employee being continuously employed by the company as of such vesting dates. The stock options have a ten-year term and an exercise price of $49.31 per share, equal to the per share closing price of Ultragenyx’s common stock on August 16, 2022.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370


All news about ULTRAGENYX PHARMACEUTICAL INC.
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/17Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies..
CI
11/15Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar..
CI
11/11Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
MT
11/10Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/10Ultragenyx Announces Departure of Chief Financial Officer
GL
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -705 M - -
Net cash 2022 760 M - -
P/E ratio 2022 -3,57x
Yield 2022 -
Capitalization 2 504 M 2 504 M -
EV / Sales 2022 4,77x
EV / Sales 2023 4,73x
Nbr of Employees 1 119
Free-Float 95,1%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 35,72 $
Average target price 97,00 $
Spread / Average Target 172%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Office
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-57.52%2 504
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.58%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930